CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, taking place on September 18-22, 2020.
Mini Oral Presentations:
| Title: | Clinical Benefit in Biomarker-Positive Patients (pts) with Locally Advanced or Metastatic Solid Tumors Treated with the PARP1/2 Inhibitor Pamiparib in Combination with Low-Dose (LD) Temozolomide (TMZ) |
| Mini Oral #: | 530MO |
| Session Title: | Developmental Therapeutics |
| Presenter: | Agostina Stradella, M.D. Catalan Institute of Oncology, Spain |
| Title: | BGB-A333, an Anti-PD-L1 Monoclonal Antibody, in Combination with Tislelizumab in Patients with Urothelial Carcinoma |
| Mini Oral #: | 535MO |
| Session Title: | Developmental Therapeutics |
| Presenter: | Juan Martin-Liberal, M.D., Ph.D., Catalan Institute of Oncology, Spain |
Poster Presentations:
| Title: | Phase 2 Study of Pamiparib in Chinese Patients (pts) with Advanced Ovarian Cancer (aOC) |
| Poster #: | 820P |
| Session Title: | Poster Display |
| Lead Author: | Xiaohua Wu, M.D., Ph.D., Fudan University Shanghai Cancer Center, China |
| Title: | Safety and Efficacy of Long-term Exposure (LTE) to Tislelizumab in Chinese Patients with Advanced Solid Tumors |
| Poster #: | 522P |
| Session Title: | Poster Display |
| Lead Author: | Lin Shen, M.D., Ph.D., Peking University Cancer Hospital & Institute , China |
| Title: | Tislelizumab + Chemotherapy vs Chemotherapy Alone as First-line Treatment for Locally Advanced/Metastatic Nonsquamous NSCLC |
| Poster #: | 1263P |
| Session Title: | Poster Display |
| Lead Author: | Shun Lu, M.D., Shanghai Chest Hospital, China |
| Title: | Updated Analysis of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC) |
| Poster #: | 1264P |
| Session Title: | Poster Display |
| Lead Author: | Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, China |
| Title: | Investigation of PD-L1 Expression and Tislelizumab Efficacy in Gastroesophageal Adenocarcinoma Using a Novel Tumor and Immune Cell Score with VENTANA PD-L1 (SP263) Assay and Combined Positive Score (CPS) |
| Poster #: | 154P |
| Session Title: | Poster Display |
| Lead Author: | Yee Chao, Ph.D., Taipei Veterans General Hospital, Taiwan |
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,100+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
| Investor Contact | Media Contact |
| Craig West | Liza Heapes or Vivian Ni |
| +1 857-302-5189 | +1 857-302-5663 or +1 857-302-7596 |
| ir@beigene.com | media@beigene.com |
